

Incremental Cost-Effectiveness Statistical Inference: Calculations and Communications.

Robert L. Obenchain
Risk Benefit Statistics, Clayton, CA 94517

December 2023

Abstract

We illustrate use of *nonparametric statistical methods* to compare alternative treatments for a particular disease or condition on both their relative effectiveness and their relative cost. These *Incremental Cost Effectiveness* (ICE) methods are based upon *Bootstrapping* (i.e. Sampling With-Replacement) using observational or clinical-trial data on individual patients. We first show how a reasonable numerical value for λ , the *Shadow Price of Health*, can be chosen using functions within the *ICEinfer* R-package when effectiveness is not measured in “QALY”s. We also argue that simple histograms are ideal for communicating key ICE findings to regulators, while our more detailed graphics may well be more informative and compelling for some health-care stakeholders.

1 Introduction

We outline and update statistical methodology needed by Health-Outcomes researchers to make powerful and robust inferences using either clinical trial or real-world (observational) data to make realistic Head-to-Head comparisons of cost and effectiveness differences between a pair of alternative

treatments for a given disease or health-care condition. We also review and illustrate use of Incremental Cost-Effectiveness “ICE Preference Maps” that can be distinctly non-linear to incorporate realistic consumer preferences from empirical health care research.

1.1 The Cost-Effectiveness Plane

As proposed in Black (1990), the *Cost-Effectiveness* plane displays measures of treatment “effectiveness” along its horizontal x -axis and measures of treatment “cost” along its vertical y -axis. This display is “Incremental” in the sense that *differences in treatment outcomes* : [“New” treatment minus “Standard” treatment] are plotted. In other words, the “ICE Origin” at $(0, 0)$ represents the relative position of the current Standard treatment. The New treatment is then relatively *More Effective* at points with x -values that are strictly positive and *Less Costly* at points with y -values that are strictly negative; see Figure 1 on page 3.

Four key axiomatic properties of ICE preference maps are listed below in Table 1. When first examining this table, it may be helpful to note that the linear “Net Benefit” preference map, $NB(x, y) = x - y$ of Stinnett and Mullahy (1998) satisfies these axioms. Subsections §3.1 through §3.5 of Obenchain (2008) provide highly detailed motivations for all four of these axioms.

TABLE 1 – Four Axioms of Coherent ICE Preferences

Indifference and Direction of Preference	$P(x, y) = 0$ when $x = y$, $P(x, y) > 0$ when $x > y$, and $P(x, y) < 0$ when $x < y$.
Monotonicity	$P(x, y) \geq P(x_o, y_o)$ for all $x \geq x_o$ and $y \leq y_o$.
Re-labeling	$P(x, y) = -P(-x, -y)$.
Symmetry and Anti-symmetry	$P(x, y) = P(-y, -x) = -P(y, x)$.




Figure 1: This graphic from Obenchain (2008) illustrates some important characteristics of coherent ICE preferences on the (Euclidean) Cost-Effectiveness plane of Black (1990). In particular, we note that preferences are **symmetric** relative to the *upper-left to lower-right diagonal line*, $x = -y$. This symmetry was first depicted graphically in Laupacis et al.(1992) and is dictated by the Fourth Axiom of Table 1.

1.2 ICE Statistical Inference: Basics

In Incremental Cost-Effectiveness inferences, Costs are always expressed in monetary units while Effectiveness is measured in units considered fully appropriate for the condition or disease being treated. The *ICEScale()* function within the *ICEinfer R-package*, Obenchain (2007-2020), facilitates choice of a numerical value for λ by calculating a purely “statistical” value. This value is the ratio of the Standard Deviations of the observed Cost and Effectiveness Differences. In the numerical example introduced below in §1.3, this ratio is $4.556/0.21309 = 21.381$.

The λ -values that I personally recommend for general use are *Integer Powers of 10*. In these cases, only the location of the decimal point on axis *tick-mark* labels change due to choice of λ . Thus the shadow price actually used in our numerical example will be simply 10 ...the *Integer Power of 10* closest to 21.381.

When cost-measurements are re-expressed using a different currency and/or alternative effect-measures are reported, the *ICEScale()* function typically proposes using a different “Integer Power of 10” shadow price. Plots generated by functions within the *ICEinfer R-package* may also adjust the aspect ratio of a plot to make it appear more nearly “Square”.

Some regulatory authorities and “Health Outcomes” researchers prefer expressing treatment Effectiveness in Quality Adjusted Life Years (QALYs) preserved; see: Weinstein, Torrance and McGuire (2009) or Neumann, Cohen and Weinstein (2014). Unfortunately, re-expressing effectiveness estimates in QALYs can be both difficult and **highly subjective** ...especially when the condition being treated is **not life-threatening**.

1.3 ICE Preferences

The ICE Preference Maps (functions) introduced in Obenchain (2008) are of the general form:

$$P(x, y) \propto (x^2 + y^2)^{(\beta-\gamma)/2} [x - y]^\gamma, \quad (1)$$

where \propto means “is proportional to”, β and γ are strictly positive “power” parameters, and the special notation $[z]^c$ denotes a “signed-power.” Specifically, $[z]^c$ denotes the product of $\text{sign}(z)$, which is +1, 0 or -1, times the absolute value of z raised to the power c . Special care is taken in expressing equation (1) because non-integer powers of negative real numbers are generally imaginary. ICE

preferences need to be expressed as real values even though they may provide only ordinal measures of preference strength.

It is straight-forward to verify that all ICE maps of form (1) satisfy axioms 1, 3 and 4 of Table 1. The *linear preference map*, $NB(x, y) = x - y$ of Stinnett and Mullahy (1998) is the special case where $\beta = \gamma = 1$.

To satisfy axiom 2, the following restriction on the ratio of the γ and β *power parameters* is required:

$$0.1715729... = 1/\Omega \leq \gamma/\beta \leq \Omega = (1 + \sqrt{2})^2 = 5.828427... \quad (2)$$

For a given numerical value of λ , the difference in *Effectiveness* between treatments, ΔE , can be re-expressed in cost units via multiplication: $\lambda \times \Delta E$. Similarly, a difference in Cost between treatments, ΔC , would be converted into Effectiveness units by division: $\Delta C/\lambda$.

1.4 Returns-to-Scale

Suppose now that the observed treatment differences in cost, y , and effectiveness, x , are somehow both multiplied by a strictly positive and finite real valued factor, f . In other words, the observed effectiveness difference of x becomes $f * x$, while the observed cost difference of y becomes $f * y$. The resulting new value of preference in Equation 1 is then:

$$P(f * x, f * y) \propto f^{(\beta-\gamma)+\gamma} * (x^2 + y^2)^{(\beta-\gamma)/2} * [x - y]^\gamma \propto f^\beta * P(x, y). \quad (3)$$

In other words, for every map in our 2-parameter family, returns-to-scale depend solely upon the β power parameter associated with only the ICE radius factor. Specifically, *returns-to-scale* will be:

- Decreasing** when $0 < \beta < 1$;
- Constant** [linear] when $\beta = 1$; or
- Increasing** when $\beta > 1$ and finite.

1.5 A Numerical Example using simulated Effectiveness and Cost Data

Table [2] provides Summary Statistics for the patient-level data that we will analyze to illustrate basic concepts.




Figure 2: Simulated data on 200 patients illustrate the case where the *Shadow Price of Health* is taken to be $\lambda = 10$. The dataset contains 99 patients (colored Red) who received the “Standard Treatment” and 101 patients (colored Blue) who received the “New Treatment.” The solid Red and Blue points correspond to the two sample **Means** of $x = Effe$ and $y = Cost$ coordinates. While these two mean-values suggest that “New” could be both less costly and more effective than the “Std” treatment, our objective will be to estimate the statistical confidence that is associated with this possibility.

TABLE 2 – Summary Statistics for the Effe-Cost Example

Variable	Min.	1st.Qt	Median	Mean	3rd.Qt	Max.
99 Std. Treatment Patients						
effe	0.076	2.436	3.615	3.653	4.624	8.373
cost	0.288	53.857	78.073	76.497	98.436	172.0
101 New Treatment Patients						
effe	0.816	3.210	3.890	4.000	5.079	8.373
cost	11.99	48.33	63.39	68.82	90.68	150.81

1.6 Wedge Shaped ICE Confidence Regions

The *ICE Statistical Inferences* of interest concern *Two Distinct Dimensions*: Cost and Effectiveness. Furthermore, two (or more) treatments are to be compared within both of these dimensions; see Laupacis, Feeny, Detsky and Tugwell (1992). Early proponents of using polar coordinates in ICE calculations were Obenchain (1997) as well as Cook and Heyse (2000). To this day, most “Health Economists” talk only about *Ratios* and Cartesian (rectangular) coordinates.

The first “Wedge Shaped” Confidence Regions were strictly *parametric* regions that assumed observed data followed a Bivariate Normal distribution and used approximations to Fieller’s Theorem (1954). The accuracy of this approach was greatly improved by Chaudhary and Stearns (1996), and it was subsequently found that these regions are frequently *highly similar* to those produced by Bootstrapping.

Typical analyses examine treatment differences of the form (*New – Std*), which can be viewed as placing the *Std*–treatment at the “ICE Origin”, (0, 0), shown as the Solid Red Dot in each panel of Figure 3. The (*New – Std*) difference is then represented by the Solid Blue points in each panel of Figure 3. Several properties of the “Wedge Shaped” (Bootstrap) ICE Confidence Regions are pointed out in the detailed captions of Figures 3 and 4.




Figure 3: Although the two alternative ICE perspectives (alias and alibi) depicted here typically scale the Effe and Cost axes differently, these perspectives still have much in common. Note that the Solid Red point in Figure 2 appears at the ICE origin in each of these plots, while the Solid Blue “New” treatment means appear near the numerical *Centroid* of each Bootstrap scatter. Close examination of the points near the edges of these somewhat “elliptical” scatters confirms that both depict the *same bootstrap scatter* containing $R = 25000$ replications. Since 688 ICE Angle order-statistics (Black Dots) are (clockwise) below the “lower limit” of the *Central Wedge* and 562 are (counter-clockwise) above the Wedge “upper limit”, each wedge contains $25000 - 688 - 562 = 23750$ replications. The *Confidence Level* of both of these wedges is thus 95%.

ICE Alias Wedge with Preference Colors




Figure 4: The 95% ICE Alias *Confidence Wedge* of Figure 3 is “Re-Colored” here using the *ICE Omega* Preference Map that is as “nonlinear” as is possible and yet still satisfy *Axiom Two: Monotonicity*. The ICE Alias perspective in this (large) plot is identical to that of the left-hand sub-plot in Figure 3. Note that there are *many more numerically small* preferences (colored Yellow) within this 95% Confidence Wedge than within the same wedge on Figure 3.

1.7 The Cost-Effectiveness Frontier

Our example a “Cost-Effectiveness Frontier”, depicted below in Figure 5, is based upon one published by the *Health Economics Resource Center, U.S. Veterans Affairs.gov*. I have added a point labeled “WW” with $effe = 0$ and $cost = 0$ that represents a hypothetical treatment strategy called *Watchful Waiting*.

If data on measures of Effectiveness and Cost are available on patients receiving treatments **B**, **C** or **D**, functions within the *ICEinfer* R-package could be used to compare outcomes on **C** with any “Mixture” of patients receiving treatments **B** or **D**. Many such “Mixtures” may well prove to be more Cost-Effective than treatment with option **C**.

2 Recommendations

The right-hand sides of Figures 6 and 7 on pages 12 and 13 illustrate the ICE Statistical Inference perspectives championed here. Numerous consumer research studies have reported that preferences typically are distinctly *nonlinear* ...as depicted in the right-hand “map” of Figure 6. When communicating study findings, we recommend following the “KISS Principle” of Zellner (1991, 2001): *Keep It Sophisticatedly Simple!*

Both histograms illustrated in Figure 7 are highly favorable to use of the “New” treatment over the “Std” ...i.e. both contain only *strictly positive estimates* of preference for “New”. While the left-hand histogram suggests stronger (more positive) preferences, this less-sophisticated (linear) analysis could easily be “badly biased”. While I recommend presenting both histograms to all interested parties, the more-sophisticated (nonlinear) analysis is both more conservative and potentially more realistic. In fact, this sort of non-linearity strikes me as being more likely to be confirmed by evidence from actual practice.

3 Summary

This paper has outlined and updated the statistical methodology needed by Health-Outcomes researchers to make powerful and robust inferences using either clinical or real-world (observational) data to make realistic Head-to-Head comparisons of cost and effectiveness differences between a pair of alternative treatments for a given disease or health-care condition. The Cost-Effectiveness “ICE

Cost-Effectiveness Frontier




Figure 5: Treatment option **A** on this graphic is (strictly) dominated by **B**, which is both *more effective* and *less costly* than **A**. Next, note that while treatment **C** is more effective than **B** and less costly than **D**, treatment **C** is strictly above the straight line segment connecting treatment options **B** and **D**. Thus, treatment **C** is said to be *Extendedly Dominated* by some *mixture* of treatment options **B** and **D**. The 5 treatment options actually on the “Cost-Effectiveness Frontier” are thus: **WW**, **STD**, **B**, **D** and **E**.




Figure 6: When $\lambda = 1$ and $\beta = 1$ (linear returns), note that there are numerous clear differences between the *ICE Preference Maps* for traditional (linear) “Net Benefit” ($\gamma = \eta = 1$) on the Left and the (highly nonlinear) “ICE Omega” map on the Right ($\gamma = \eta = 5.828$). Note that both Maps are colored Yellow towards Green (numerically positive values) below their lower-left to upper-right diagonal, and Tan towards Red (numerically negative values) above that same diagonal. In fact, note also that the “Net Benefit” map is essentially “One - Dimensional” (i.e. color depends only on the scalar *Effe-Cost difference*) while the nonlinear map is fully “Two - Dimensional”.




Figure 7: These two simple Histograms illustrate both similarities and differences between the potentially over-simplistic “Net Benefit” evaluation on the Left and the potentially more realistic (and distinctly nonlinear) ICE Omega Preference Map (shown in Figure 4) on the Right. The pure simplicity of these graphics may make them ideal for convincing Health-Care administrators and regulators that the “New” Treatment delivers outcomes with superior Cost-Effectiveness relative to the “Std” Treatment. Since the Right-Hand Histogram quantifies Non-Linear preferences, it probably portrays a slightly more realistic (less optimistic) evaluation.

Preference Map” used in this approach can be distinctly non-linear to incorporate truly realistic consumer preferences from empirical health care research.

Over the last 50 years, computers have helped shape statistical theory as well as its practice. Freely available software can provide computational and visual fast-tracks into the strengths and weaknesses of alternative statistical methods. Why not analyze hundreds or thousands of numbers using millions or billions of calculations, Efron (1979). In reality, **R** functions, R-Core Team (2023), are almost indispensable tools for today’s students, teachers, applied researchers and data-scientists who use and/or extend existing computational and visualization methodologies.

References

- [1] Black W. C. (1990). “The CE plane: a graphic representation of cost-effectiveness.” *Medical Decision Making* 10: 212–214.
- [2] Briggs A.H. and Fenn P. (1998). “Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane.” (Student Corner.) *Health Economics* 7: 723–740.
- [3] Chaudhary M. A. and Stearns S. C. (1996). “Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial.” *Statistics in Medicine* 15: 1447–1458.
- [4] Cook J. R. and Heyse J. F. (2000). “Use of an angular transformation for ratio estimation in cost-effectiveness analysis.” *Statistics in Medicine* 19: 2989–3003.
- [5] Efron B. (1979). “Computers and the Theory of Statistics: Thinking the Unthinkable.” *SIAM Review* 21(4): 460–480.
- [6] Fieller E. C. (1954). “Some problems in interval estimation.” *Journal Royal Statistical Society, Series B* 16: 175–183.
- [7] Gold M. R., Siegel J. E., Russell L. B. and Weinstein M.C., eds. (1996). *Cost-effectiveness in health and medicine*. New York: Oxford University Press.
- [8] Laupacis A., Feeny, D., Detsky, A. S. and Tugwell P. X. (1992). “How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.” *Can. Med. Assoc. J.* 146(4): 473–481.

- [9] Weinstein, M. C., Torrance, G. E. and McGuire, Alistair. (2009). “QALYs: The Basics” *Value in Health* 12: S5–S9. DOI: 10.1111/j.1524-4733.2009.00515.x
- [10] Neumann P. J., Cohen J. T. and Weinstein M. C. (2014). “Updating Cost-Effectiveness - The Curious Resilience of the \$50,000-per-QALY Threshold.” *NEJM* 371: 796–797.
- [11] Obenchain R. L. (1997). “Issues and Algorithms in Cost-Effectiveness Inference.” *Biopharmaceutical Reports*, American Statistical Association, 5(2): 1–7.
- [12] Obenchain R. L. (2007-2020). “ICEinfer CRAN Package: Incremental Cost-Effectiveness Inference using Two Unbiased Samples.” Ver. 1.3., <https://CRAN.R-project.org/package=ICEinfer>
- [13] Obenchain R. L. (2008). “ICE Preference Maps: Nonlinear Generalizations of Net Benefit and Acceptability.” *Health Services and Outcomes Research Methodology* 8: 31–56. Springer “Open Access”, DOI: 10.1007/s10742-007-0027-2.
- [14] R-Core Team. (2023). “R: A language and environment for statistical computing.” R Foundation for Statistical Computing, Vienna, Austria. <https://CRAN.R-project.org>
- [15] Stinnett, A. A. and Mullahy, J. (1998). “Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. *Medical Decision Making*, Special Issue on Pharmacoeconomics. 18, S68–S80.
- [16] Zellner, A. (1991). “The KISS Principle.” ASA Presidential Address, Atlanta, GA.
- [17] Zellner, A. (2001). “Statistics, Econometrics and Forecasting.” 242–261. Cambridge Univ. Press.